<DOC>
	<DOCNO>NCT02339324</DOCNO>
	<brief_summary>This study plan estimate safety profile combination biotherapy regimen consist standard-dose interferon alpha-2b ( HDI ) anti-PD1 monoclonal antibody , Pembrolizumab , neoadjuvant therapy locally/regionally advanced/recurrent melanoma . Also , objectives trial include evaluation prognostic predictive biomarkers , radiologic preoperative response rate , pathologic response rate , progression free survival overall survival . Up 30 evaluable patient accrue .</brief_summary>
	<brief_title>Neoadjuvant Combination Biotherapy With Pembrolizumab High Dose IFN-alfa2b</brief_title>
	<detailed_description>The study 3 main phase : Induction Phase : Pembrolizumab I.V . infusion every 3-4 week 2 dos ( start first week HDI administration ) give concurrently HDI I.V . x 5 consecutive day 7 every week 4 week , follow S.C. every day 3 time week 2 week . This follow definitive surgery ( week 6-8 ) . Maintenance Phase ( follow recovery surgery ) : Pembrolizumab I.V . infusion every 3 week give concurrently HDI S.C. QOD TIW every week 46 additional week .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Able provide write informed consent . 2 . At least 18 year age . 3 . Melanoma belong follow stage : Tx T14 N1b , N2b , N2c , N3 M 0 Pts eligible trial either presentation primary melanoma concurrent regional nodal and/or intransit metastasis , time clinically detect nodal and/or intransit recurrence may belong follow group : Primary melanoma clinically apparent regional lymph node metastasis . Clinically detected recurrence melanoma proximal regional lymph node ( ) basin . Clinically detected primary melanoma involve multiple regional nodal group . Clinically detect single site nodal metastatic melanoma arise unknown primary . Pts intransit satelite metastasis without lymph node involvement allow consider potentially surgically resectable baseline . NOTE : A pt determine potentially surgically resectable baseline eligible neoadjuvant study . 4 . Have measurable disease . 5 . Provide tumor tissue newly obtain biopsy . 6 . ECOG performance status 0 1 . 7 . Adequate organ function . 1 . Is currently participate participate study investigational agent use investigational device within 4 wks first dose treatment . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 wks prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 4 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . 5 . Has active automimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . 6 . Has evidence interstitial lung disease active , noninfectious pneumonitis . 7 . Has active infection require systemic therapy . 8 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 9 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 10 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 11 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Prior treatment interferon alfa allow . Patients history allergic hypersensitivity reaction interferon alfa exclude . 12 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 13 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . 14 . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>